Abstract
In order to improve the efficacy of first generation adenoviral vectors for glioma treatment, we designed conditionally replicating viruses in which the E1A gene is under the control of the promoter (gfa2) of the glia specific intermediate filament Glial Fibrillary Acidic Protein (GFAP) and similar constructs containing additional glial specific enhancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
